Usefulness of monoclonal antibody Ki-67 as a prognostic factor of hepatocellular carcinoma

International Hepatology Communications

Volumn 6, Issue 5, 1997, Pages 209-218

  Yoshimoto, Jiro ^a   Iwata, Toyohito ^a   Takamori, Shigeru ^a   Kojima, Kuniaki ^a   Futagawa, Shunji ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

hepatocellular carcinoma; immunohistochemistry; Ki 67; prognosis

Indexed keywords

MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CHRONIC HEPATITIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; NECROSIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

EID: 0031080353     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-4346(96)00345-3     Document Type: Article

References (14)

1. [1] Kitamoto M, Nakanishi T, Kira S, et al. DNA ploidy pattern and proliferating cell nuclear antigen (PCNA) labeling index in small hepatocellular carcinoma. Acta Hepatol Jpn 1994; 35(8): 596-600 (in Japanese).
2. [2] Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13-20.
3. [3] Irene OLNG, JIA NA, Edward GSLAI, ST FAN, Matthew NG. Ki-67 antigen expression in hepatocellular carcinoma using monoclonal antibody MIB-1. Anat Pathol 1995; 104(3): 313-318.
4. [4] Youssef Emile M, Tsutomu Matsuda, Nobuyasu Takada, et al. Prognostic significance of the MIB-1 proliferation index for patients with squamous cell carcinoma of the esophagus. Cancer 1995; 76(3): 358-366.
5. [5] Porschen R, Lohe B, Hengels KJ, Borchard F. Assessment of cell proliferation in colorectal carcinomas using the monoclonal antibody Ki-67. Cancer 1989; 64: 2501-2505.
6. [6] Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991; 39: 741-748.
7. [7] Liver cancer study group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 3rd ed. Tokyo: Kanehara, 1992 (in Japanese).
8. [8] Maeda K, Yong-Suk Chung, Onoda N, et al. Proliferating cell nuclear antigen labeling index in early gastric cancer using preoperative biopsy specimens. Jpn J Gastroenterol Surg 1993; 26(12): 2740-2744 (in Japanese).
9. [9] Kawamura M, Sato T, Tsushima H, et al. Clinicopathological study of mucinous adenocarcinoma of the stomach. Jpn J Gastroenterol Surg 1994; 27(1): 10-16 (in Japanese).
10. [10] Trere D, Farabegori F, Cancellieri A, Ceccarelli C, Eusebi V, Derenzini M. AgNOR area in interphase nuclei of human tumours correlates with the proliferative activity evaluated by bromodeoxyuridine labelling and Ki-67 immunostaining. J Pathol 1991; 165: 53-59.
11. [11] Hino O. Cancer genes in hepatocarcinogenesis. Kan Tan Sui 1992; 25(6): 1119-1122 (in Japanese).
12. [12] Tarao K, Shimizu A, Ookawa S, Tamai S. Role of increased DNA synthesis activity of hepatocytes in multicentric hepatocarcinogenesis in residual liver of hepatectomized cirrhotic patients with hepatocellar carcinoma. Kan Tan Sui 1995; 31(2): 195-207 (in Japanese).
13. [13] Matsumoto Y, Miyasaka Y, Matsuda M, Nagahori K, Yamamoto M. Prognostic evaluation of hepatocellular carcinoma by serial changes of serum AFP levels in hepatoma patients. Clin Gastroenterol 1995; 10(12): 1799-1809 (in Japanese).
14. [14] Yamanaka N, Okamoto E, Oriyama T, et al. Treatment selection for small sized hepatocellular carcinoma. Gastroenterol Surg 1995; 18(4): 429-435 (in Japanese).